MediBIC is a leading biotechnology company in Japan specializing in Pharmacogenomics (PGx). We have been building a foundation for
personalized medicine in Japan since the early days of research in this
area through development of internal in-silico capabilities and external
partnerships with technology providers and domain experts.

Japan, although lagging behind the U.S. in implementing PGx and
personalized medicine, is making substantial progress forward both
academically through its national research programs and in the
pharmaceutical industry. The Japanese regulatory agencies have also
been quite active in keeping abreast of the developments in this area.

MediBIC was established in early 2000 and went public on Tokyo Stock
Exchange in September of 2003. The companies to focus on its core
businesses and expand into new areas of activity. It recently became
a holding company “MediBIC Group” with these subsidiaries focusing
on drug development, biomarker development support, and, investment
and incubation business.

All of our businesses utilize our expertise in pharmaceutical consulting
and our global network. We have built strong collaborations in Asia in
support of our biomarker discovery consulting and investment businesses
and look to further expand our base in Asia.

For the companies who are considering expansion of their biotechnology
business into Asian market including Japan, we offer a portal to broaden
your business chance with our networks and rich experiences in drug
development.

Sincerely,
Yasuhiro Hashimoto, M.D.